Novartis CEO Explains Delay In Telling US FDA About Zolgensma Data Fraud: We Wanted To Understand It First
Novartis is in the process of "exiting" the "small number" of scientists involved in the fraud, CEO Narasimhan says.
Novartis is in the process of "exiting" the "small number" of scientists involved in the fraud, CEO Narasimhan says.